Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 3, 2011, Pages 228-239

  Visscher, Henk ^a,b   Amstutz, Ursula ^a,b,c   Sistonen, Johanna ^a,b   Ross, Colin J ^a,b   Hayden, Michael R ^a,b   Carleton, Bruce C ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

Author keywords

adverse drug reactions; pediatrics; pharmacogenetics; pharmacogenomics

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BUCINDOLOL; CARVEDILOL; CLOPIDOGREL; CYTOCHROME P450 2C9; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; GASTROINTESTINAL AGENT; GLYCOPROTEIN P; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; IRBESARTAN; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; PERINDOPRIL; PROPRANOLOL; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TICAGRELOR; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

B CELL LYMPHOMA; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CARDIOTOXICITY; CHILDHOOD CANCER; CORONARY STENT; DNA DAMAGE; DRUG BINDING; DRUG EFFICACY; DRUG LABELING; DRUG RESPONSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEART ARRHYTHMIA; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LENGTH OF STAY; LIPID PEROXIDATION; LONG QT SYNDROME; LYMPHATIC LEUKEMIA; MORTALITY; PEDIATRIC CARDIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; STROKE; SUDDEN DEATH; TORSADE DES POINTES;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CARDIOTOXINS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHILD; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES;

EID: 80052769827     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182163b82     Document Type: Review

References (153)

1. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119-137. (Pubitemid 43261982)
2. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology drug disposition, action, and therapy in infants and children. NEngl JMed. 2003;349:1157-1167. (Pubitemid 37122329)
3. Hines RN. The ontogeny ofdrug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118:250-267.
4. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharma-cogenetics. Trends Mol Med. 2001;7:201-204.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence ofadverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205. (Pubitemid 28193431)
6. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921. (Pubitemid 32165345)
7. International Hap Map Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
8. Leeder JS, Kearns GL, Spielberg SP, et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol. 2010;50:1377-1387.
9. Chan YC, Valenti D, Mansfield AO, et al. Warfarin induced skin necrosis. Br J Surg. 2000;87:266-272. (Pubitemid 30156350)
10. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900.
11. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296:1858-1866. (Pubitemid 44596195)
12. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006; 16:101-110. (Pubitemid 43145678)
13. Wallin R, Hutson SM. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol Med. 2004;10:299-302. (Pubitemid 38881516)
14. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7:99-111. (Pubitemid 46567142)
15. Sistonen J, Fuselli S, Palo JU, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009;19:170-179.
16. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a Hu GEnet systematic review andmeta-analysis. Genet Med. 2005;7:97-104. (Pubitemid 40261834)
17. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation andwarfarin dose. N Engl J Med. 2005;352: 2285-2293. (Pubitemid 40740552)
18. Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008;112: 1013-1021.
19. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115:3827-3834.
20. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87: 572-578.
21. Vecsler M, Loebstein R, Almog S, et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 2006;95:205-211.
22. Borgiani P, Ciccacci C, Forte V et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009;10:261-266.
23. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-4112.
24. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112:1022-1027.
25. Sagreiya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics. 2010;20:407-413.
26. Takeuchi F, Mc Ginnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLo S Genet. Mar 2009;5:e1000433.
27. Fanikos J, Grasso-Correnti N, Shah R, et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol. 2005;96:595-598. (Pubitemid 41132782)
28. Mc William A, Lutter R, Nardinelli C. Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin. American Enterprise Institute-Brookings Joint Center, Working Paper. 2006;06-23.
29. FDA. Pharmacology Subcommittee Meeting of the Advisory Committee for Pharmaceutical Science, November 15. Advisory Committee for Pharmaceutical Science. Available at : http://www.fda.gov/ohrms/ dockets/ac/05/minutes/2005- 4194M1. pdf. Accessed November 20, 2010.
30. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360: 753-764.
31. Thornburg CD, Jones E, Bomgaars L, et al. Pediatric warfarin practice and pharmacogenetic testing. Thromb Res. 2010;126:e144-e146.
32. Nowak-Gottl U, Dietrich K, Schaffranek D, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116:6101-6105.
33. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68:541-555.
34. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004; 308:965-974. (Pubitemid 38263972)
35. Itoh S, Onishi S. Developmental changes of vitamin K epoxidase and reductase activities involved in the vitamin K cycle in human liver. Early Hum Dev. 2000;57:15-23. (Pubitemid 30006875)
36. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
37. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95: 362-372.
38. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). JAm Coll Cardiol. 2010;55:2804-2812.
39. Carleton B. Gene-based warfarin dosing. Ther Drug Monit. 2010;32:332.
40. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment plateletreactivity. Circulation. 2003;107:2908-2913. (Pubitemid 36736631)
41. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacody-namic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-2436. (Pubitemid 350154353)
42. Savi P, Herbert JM, Pflieger AM, et al. Importance ofhepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992;44:527-532.
43. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30: 1288-1295. (Pubitemid 35265838)
44. Kazui M, Nishiya Y Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
45. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247. (Pubitemid 44497506)
46. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17:1057-1064. (Pubitemid 351339490)
47. Fontana P, Senouf D, Mach F Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res. 2008;121:463-468. (Pubitemid 351174278)
48. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-317.
49. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. NEngl JMed. 2009;360:354-362.
50. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl JMed. 2009; 360:363-375.
51. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy ofclopidogrel therapy JAMA. 2009;302:849-857.
52. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320-1328.
53. Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res. 1998;37: 429-435. (Pubitemid 28306478)
54. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501. (Pubitemid 44767878)
55. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312-1319.
56. FDA. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at http://wwwfda.gov/Drugs/Drug Safety/Postmarket Drug Safety Information for Patientsand Providers/ucm203888.htm. Accessed November 20, 2010.
57. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA 'boxed warning' a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537-557.
58. Gentilomo C, Huang YS, Raffini L. Significant increase in clopidogrel use across US children's hospitals. Pediatr Cardiol. 2011;32:167-175.
59. Finkelstein Y Nurmohamed L, Avner M, et al. Clopidogrel use in children. JPediatr. 2005;147:657-661. (Pubitemid 41598340)
60. Soman T, Rafay MF, Hune S,etal. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. Stroke. 2006;37:1120-1122.
61. Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On c LOpidogrel (PICOLO) trial. Circulation. 2008;117:553-559.
62. Caruthers RL, Dorsch MP. Letter by Caruthers and Dorsch regarding article, 'Dosing ofclopidogrel for platelet inhibition in infants and young children: primary results of the platelet inhibition in children on c LOpidogrel (PICOLO) trial.' Circulation. 2008;118:e120; author reply e121.
63. Lopez-Sendon J, Swedberg K, Mc Murray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25: 1341-1362.
64. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacother-apy. 2007;27:874-887.
65. Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev. 2010;15:187-196.
66. Liberman JN, Berger JE, Lewis M. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents. Arch Pediatr Adolesc Med. 2009;163:357-364.
67. Bruns LA, Canter CE. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? Paediatr Drugs. 2002;4: 771-778. (Pubitemid 36005722)
68. Zineh I, Pacanowski M. Cardiovascular diseases. In: Perrin NM, ed. Pharmacogenomics: Applications to Patient Care. 2nd ed. Lenexa, KS: American College of Clinical Pharmacy; 2009:176-203.
69. Hoecht C, Bertera FM, Mayer MA, et al. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antago-nists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol. 2010;6:199-211.
70. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol. 2006;44:107-118. (Pubitemid 43082210)
71. de Boer RA, van der Harst P, van Veldhuisen DJ, et al. Pharmacogenetics in heart failure: promises and challenges. Expert Opin Pharmacother. 2009;10:1713-1725.
72. Moore JD, Mason DA, Green SA, et al. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis ofc145A>G and c1165G>C. Hum Mutat 1999;14:271.
73. Mason DA, Moore JD, Green SA, et al. A gain-of-function poly-morphism in a G-protein coupling domain of the human beta1-adrenergic receptor. JBiol Chem. 1999;274:12670-12674.
74. Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33:9414-9419. (Pubitemid 24272896)
75. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300-1305. (Pubitemid 37279854)
76. Rathz DA, Brown KM, Kramer LA, et al. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol. 2002;39:155-160. (Pubitemid 34093534)
77. O'Shaughnessy KM, Fu B, Dickerson C, et al. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci. 2000;99:233-238.
78. de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharma-cogenet Genomics. 2005;15:137-142. (Pubitemid 40569899)
79. Karlsson J, Lind L, Hallberg P, et al. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol. 2004;27:347-350. (Pubitemid 38703089)
80. Filigheddu F, Argiolas G, Degortes S, et al. Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics. 2010;11: 319-325.
81. Nordestgaard BG, Kontula K, Benn M, et al. Effect of ACE insertion/ deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study. Pharmacogenet Genomics. 2010;20:77-85.
82. Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy Pharmacogenet Genomics. 2005;15:227-234. (Pubitemid 40569894)
83. Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics. 2007;17:941-949. (Pubitemid 350293794)
84. Magnusson Y, Levin MC, Eggertsen R, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78:221-231. (Pubitemid 41254107)
85. Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74:44-52. (Pubitemid 36776175)
86. Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003;74:372-379. (Pubitemid 37222858)
87. Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther. 2003;73:366-371. (Pubitemid 36403596)
88. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103:11288-11293. (Pubitemid 44156511)
89. Cappello N, Rendine S, Griffo R, et al. Genetic analysis of Sardinia: I. Data on 12 polymorphisms in 21 linguistic domains. Ann Hum Genet. 1996;60:125-141. (Pubitemid 26078709)
90. Terra SG, Pauly DF, Lee CR, et al. Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005;77: 127-137. (Pubitemid 40269128)
91. Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526-1533. (Pubitemid 41362690)
92. Lobmeyer MT, Gong Y, Terra SG, et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007;17:277-282. (Pubitemid 46668051)
93. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14:510-517. (Pubitemid 351655214)
94. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
95. Rau T, Wuttke H, Michels LM, et al. Impact of the CYP2D6 genotype on the clinical effects ofmetoprolol: aprospective longitudinal study. Clin Pharmacol Ther. 2009;85:269-272.
96. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther. 2002;72:429-437. (Pubitemid 35178868)
97. Bijl MJ, Visser LE, van Schaik RH, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009;85:45-50.
98. Nozawa T, Taguchi M, Tahara K, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005;46:713-720. (Pubitemid 41527766)
99. Lefebvre J, Poirier L, Poirier P, et al. The influence of CYP2D6 phenotype on the clinical response ofnebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007;63:575-582. (Pubitemid 46632567)
100. Skeggs LT, Dorer FE, Kahn JR, et al. Biochemistry of renin-angiotensin system and its role in hypertension. Am J Med. 1976;60:737-748.
101. Brugts JJ, den Uil CA, Danser AHJ, et al. The renin-angiotensin- aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology. 2009; 112:303-312.
102. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208-1219. (Pubitemid 46527856)
103. Momma K. ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs. 2006;8:55-69.
104. Hilgers KF, Dotsch J, Rascher W, et al. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol. 2004;19:956-961. (Pubitemid 39242774)
105. Tsikouris JP, Peeters MJ. Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease. Cardiovasc Drugs Ther. 2007;21: 121-132. (Pubitemid 46834913)
106. Rigat B, Hubert C, Alhencgelas F, et al. An insertion deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86: 1343-1346. (Pubitemid 20370444)
107. Danser AHJ, Schalekamp MADH, Bax WA, et al. Angiotensin-converting enzyme in the human heart\-effect of the deletion insertion polymorphism. Circulation. 1995;92:1387-1388.
108. Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics. 2009;10:1295-1307.
109. Kitsios G, Zintzaras E. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMCMed Genet. 2009;10:50.
110. Schelleman H, Klungel OH, Witteman JCM, et al. Angiotensinogen M235T polymorphism and the risk ofmyocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet. 2007;15:478-484. (Pubitemid 46487703)
111. Bis JC, Smith NL, Psaty BM, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am JHypertens. 2003;16:1011-1017. (Pubitemid 37500795)
112. Schelleman H, Klungel OH, Witteman JCM, et al. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myo-cardial infarction and stroke. Pharmacogenomics J. 2008;8:400-407.
113. Lynch AI, Arnett DK, Davis BR, et al. Sex-specific effects of AGT-6 and ACEI/D on pulse pressure after 6 months on antihypertensive treatment: the Gen HAT study. Ann Hum Genet. 2007;71:735-745. (Pubitemid 47517257)
114. Brugts JJ, Isaacs A, Boersma E, et al. Genetic determinants oftreatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J. 2010;31:1854-1864.
115. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. JHypertens. 2001;19:1783-1787. (Pubitemid 32924944)
116. Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during anti hypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. JHypertens. 2002;20:657-663. (Pubitemid 34913709)
117. Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. JHypertens. 2002;20:2089-2093. (Pubitemid 35305508)
118. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response. Am JHypertens. 2002;15:389-393.
119. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022. (Pubitemid 38269278)
120. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br JClin Pharmacol. 2010;70:16-23.
121. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008;154:1502-1507.
122. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007-2012. (Pubitemid 41435722)
123. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891-899. (Pubitemid 46809861)
124. Aerssens J, Paulussen AD. Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics. 2005;6:259-270. (Pubitemid 40601629)
125. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. JMol Med. 2004;82:182-188. (Pubitemid 38392168)
126. Bellocq C, Wilders R, Schott JJ, et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol. 2004;66:1093-1102. (Pubitemid 39411050)
127. Schulze-Bahr E. Susceptibility genes & modifiers for cardiac arrhyth-mias. Prog Biophys Mol Biol. 2008;98:289-300.
128. Lehtonen A, Fodstad H, Laitinen-Forsblom P, et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm. 2007;4:603-607. (Pubitemid 46655584)
129. Dorado P, Berecz R, Penas-Lledo EM, et al. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin Drug Metab Toxicol. 2007;3:9-19. (Pubitemid 47315416)
130. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5:243-272. (Pubitemid 38499965)
131. Vos MA, Paulussen AD. Genetic basis ofdrug-induced arrhythmias. Ann Med. 2004;36(suppl 1):35-40.
132. Treluyer JM, Rey E, Sonnier M, et al. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol. 2001;52:419-425. (Pubitemid 32939444)
133. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther. 2003;74:312-325. (Pubitemid 37222852)
134. Arking DE, Pfeufer A, Post W, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet. 2006;38:644-651. (Pubitemid 43927305)
135. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Commonvariants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet. 2009;41:399-406.
136. Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009;41:407-414.
137. Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2010 Oct 5 [Epub ahead ofprint].
138. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14: 1024-1031.
139. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94: 525-533. (Pubitemid 351441417)
140. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-829. (Pubitemid 34752678)
141. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-2636. (Pubitemid 46179451)
142. Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13:503-512. (Pubitemid 34461132)
143. van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42:3191-3198. (Pubitemid 44872945)
144. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229. (Pubitemid 38720829)
145. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycincardiotoxicity. Cancer. 1973;32:302-314.
146. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717. (Pubitemid 10218041)
147. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associ-ated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112: 3754-3762. (Pubitemid 43739516)
148. Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia. 2009;23:1118-1126.
149. Rajic V Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009;50:1693-1698.
150. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789-2795. (Pubitemid 351969225)
151. Blanco JG, Sun C, Landier W, et al. Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: a Children's Oncology Group study. J Clin Oncol (Meeting Abstracts). 2010; 28(suppl):9512.
152. Carleton B, Poole R, Smith M, et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf. 2009;18:713-721.
153. Loo TT, Ross CJ, Sistonen J, et al. Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmaco-genomics. 2010;11:1269-1285.